CRP and susceptibility to pneumonia measurement: Likewise, Salvarani et al [6] showed no benefit of tocilizumab early administration in a selected population of severe (but not critical) pneumonia (median PaO2/FiO2 at 264.5 mmHq), which had a very low level of systemic inflammation (median C-reactive protein at 8.2 mg/L).